Tyme Technologies, Inc. (TYME): Price and Financial Metrics


Tyme Technologies, Inc. (TYME): $0.27

-0.01 (-3.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TYME Stock Price Chart Interactive Chart >

Price chart for TYME

TYME Price/Volume Stats

Current price $0.27 52-week high $2.02
Prev. close $0.28 52-week low $0.22
Day low $0.26 Volume 710,100
Day high $0.29 Avg. volume 799,655
50-day MA $0.28 Dividend yield N/A
200-day MA $0.55 Market Cap 46.53M

Tyme Technologies, Inc. (TYME) Company Bio


Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.


TYME Latest News Stream


Event/Time News Detail
Loading, please wait...

TYME Latest Social Stream


Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.

The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued?

Tyme Technologies Inc. (NASDAQ:TYME) shares, rose in value on Friday, 02/18/22, with the stock price down by -0.32% to the previous days close as strong demand from buyers drove the stock to $0.34. Actively observing the price movement in the last trading, the stock closed the session at $0.34, falling within a range of $0.3305 The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued? Read More »

Stocks Register | February 19, 2022

TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™),

Business Wire | February 11, 2022

Tyme Technologies, Inc.''s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 11, 2022

Tyme Technologies GAAP EPS of -$0.03

Tyme Technologies press release (TYME): FQ3 GAAP EPS of -$0.03.The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s…

Seeking Alpha | February 11, 2022

TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET

BEDMINSTER, N.J., January 27, 2022--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.

Yahoo | January 27, 2022

Read More 'TYME' Stories Here

TYME Price Returns

1-mo 8.91%
3-mo -23.32%
6-mo -60.49%
1-year -77.50%
3-year -77.87%
5-year -91.00%
YTD -55.23%
2021 -50.57%
2020 -12.86%
2019 -62.06%
2018 -42.16%
2017 70.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6103 seconds.